Drug-discovery company Critical Therapeutics Inc. on Wednesday reported positive results from an early- to mid-stage clinical trial of its Zyflo zileuton IV asthma drug.
The study found that patients who received the drug showed greater improvement in lung function than patients who received a placebo. The drug was well tolerated at all doses, with no serious adverse events reported in the trial, the company said.
Critical Therapeutics is developing the drug initially for use in emergency room or urgent care centers for patients who have acute flair ups of asthma.
Shares rose to $3.88 19.2% to $1.55.
Device maker Medtronic's (MDT) shares were all over the map. While the company met its lowered guidance for the fiscal first quarter, it reduced its full-year forecast. Lately, the stock was up 4 cents, or 0.1%, to $45.40.
Shares of drug developer SuperGen (SUPG) fell after the company announced the closing of a deal with Mayne Pharma. Mayne will pay around $34 million for SuperGen's Nipent injection and SurfaceSafe cleaner. However, payments will depend on product performance and key events, according to SuperGen. Shares dipped 0.9% to $3.40.
Bristol-Myers Squibb (BMY) slipped after Cell Therapeutics (CTIC) announced positive data on its cancer drug Xyotax, a potential competitor to Taxol. Bristol's shares fell 1.2% to $21.58.
Other movers included Celgene (CELG) , whose shares fell 2.4% to $40.98, Avalon Pharmaceuticals (AVRX) , down 3.5% to $3.07, Meridian Bioscience (VIVO) , falling 3% to $22.70, GeoPharma (GORX) , down 5.5% to $3.08, Hollis-Eden Pharmaceuticals (HEPH) , off 2.2% to $6.97, and Medicines Co. (MDCO) , down 1.7% to $21.99.
Onyx Pharmaceuticals (ONXX) gained 6% to $14.11, Novavax (NVAX) was up 6.8% to $3.94, EpiCept (EPCT) was rising 6.2% to $2.39, GenVec (GNVC) was up 6% to $1.23, and Hemispherx Biopharma (HEB) got a 3.8% boost to $2.19.
The study found that patients who received the drug showed greater improvement in lung function than patients who received a placebo. The drug was well tolerated at all doses, with no serious adverse events reported in the trial, the company said.
Critical Therapeutics is developing the drug initially for use in emergency room or urgent care centers for patients who have acute flair ups of asthma.
Shares rose to $3.88 19.2% to $1.55.
Device maker Medtronic's (MDT) shares were all over the map. While the company met its lowered guidance for the fiscal first quarter, it reduced its full-year forecast. Lately, the stock was up 4 cents, or 0.1%, to $45.40.
Shares of drug developer SuperGen (SUPG) fell after the company announced the closing of a deal with Mayne Pharma. Mayne will pay around $34 million for SuperGen's Nipent injection and SurfaceSafe cleaner. However, payments will depend on product performance and key events, according to SuperGen. Shares dipped 0.9% to $3.40.
Bristol-Myers Squibb (BMY) slipped after Cell Therapeutics (CTIC) announced positive data on its cancer drug Xyotax, a potential competitor to Taxol. Bristol's shares fell 1.2% to $21.58.
Other movers included Celgene (CELG) , whose shares fell 2.4% to $40.98, Avalon Pharmaceuticals (AVRX) , down 3.5% to $3.07, Meridian Bioscience (VIVO) , falling 3% to $22.70, GeoPharma (GORX) , down 5.5% to $3.08, Hollis-Eden Pharmaceuticals (HEPH) , off 2.2% to $6.97, and Medicines Co. (MDCO) , down 1.7% to $21.99.
Onyx Pharmaceuticals (ONXX) gained 6% to $14.11, Novavax (NVAX) was up 6.8% to $3.94, EpiCept (EPCT) was rising 6.2% to $2.39, GenVec (GNVC) was up 6% to $1.23, and Hemispherx Biopharma (HEB) got a 3.8% boost to $2.19.
posted by doublezero at
9:10 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home